<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03422094</url>
  </required_header>
  <id_info>
    <org_study_id>201804195</org_study_id>
    <nct_id>NCT03422094</nct_id>
  </id_info>
  <brief_title>Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma</brief_title>
  <official_title>A Pilot Study to Assess the Safety, Feasibility, and Immunogenicity of a Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single institution, open-label, multi-arm, pilot study assessing the safety,&#xD;
      feasibility, and immunogenicity of a personalized neoantigen-based vaccine plus poly-ICLC&#xD;
      (NeoVax) combined with immune checkpoint inhibitors in subjects with newly diagnosed,&#xD;
      unmethylated glioblastoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Manufacturer changed focus to cell therapy&#xD;
  </why_stopped>
  <start_date type="Actual">October 31, 2018</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">April 26, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of regimen as measured by a &lt;= 33% dose-limiting toxicity (DLT) rate for a given cohort</measure>
    <time_frame>Up to 90 days after start of treatment</time_frame>
    <description>The DLT observation period is 60 days after C1D1 for patients enrolled to Cohorts A, C, and D and is 90 days after C1D1 for patients enrolled to Cohorts B and E.&#xD;
DLT is defined as any grade 3 or greater event that occurs during the DLT observation period that is considered at least possibly related to the study treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility of generating a personalized neoantigen peptide vaccine as measured by the ability to identify candidate tumor-specific neoantigens</measure>
    <time_frame>From time of resection to 4 weeks post-radiation therapy (approximately 14 weeks)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility of generating a personalized neoantigen peptide vaccine as measured by the the ability to manufacture a neoantigen-based synthetic long peptide vaccine</measure>
    <time_frame>From time of resection to 4 weeks post-radiation therapy (approximately 14 weeks)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility of generating a personalized neoantigen peptide vaccine as measured by the ability to administer the vaccine to a patient at 4 weeks post-completion of radiotherapy</measure>
    <time_frame>From time of resection to 4 weeks post-radiation therapy (approximately 14 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of a personalized neoantigen peptide vaccine as measured by the ability to generate a measurable neoantigen-specific T cell response in vaccinated patients</measure>
    <time_frame>Week 4 post-vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of a personalized neoantigen peptide vaccine as measured by the ability to generate a measurable neoantigen-specific T cell response in vaccinated patients</measure>
    <time_frame>Week 16 post-vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of a personalized neoantigen peptide vaccine as measured by the number of individual neoantigens per number of neoantigens vaccinated against, with which a measurable T cell-specific response</measure>
    <time_frame>Week 4 post-vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of a personalized neoantigen peptide vaccine as measured by the number of individual neoantigens per number of neoantigens vaccinated against, with which a measurable T cell-specific response</measure>
    <time_frame>Week 16 post-vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of high quality candidate neoantigens present in patients with newly diagnosed glioblastoma</measure>
    <time_frame>Up to 2 weeks post sequencing</time_frame>
    <description>High quality neoantigens will be defined as those that meet criteria for inclusion in a vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free (PFS) survival rate</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) rate</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Cohort A: NeoVax+Nivolumab (start at time of progression)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NeoVax given on Days 1, 8, 15, and 22 of Cycle 1 (priming phase), and then on Day 1 of each subsequent cycle (boosting phase)&#xD;
Nivolumab 480 mg i.v. given on Day 1 of each cycle beginning at time of progression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B: NeoVax+Nivolumab (start with Cycle 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NeoVax given on Days 1, 8, 15, and 22 of Cycle 1 (priming phase), and then on Day 1 of each subsequent cycle (boosting phase)&#xD;
Nivolumab 480 mg i.v. given on Day 1 of each cycle beginning with Cycle 2 (start of boosting phase)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C: NeoVax + Nivolumab (start with Cycle 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NeoVax given on Days 1, 8, 15, and 22 of Cycle 1 (priming phase), and then on Day 1 of each subsequent cycle (boosting phase)&#xD;
Nivolumab 480 mg i.v. given on Day 1 of Cycle 1 (priming phase), and then on Day 1 of each subsequent cycle (boosting phase)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort D: NeoVax+Ipilimumab+Nivolumab (start with Cycle 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NeoVax given on Days 1, 8, 15, and 22 of Cycle 1 (priming phase), and then on Day 1 of each subsequent cycle (boosting phase)&#xD;
Ipilimumab 1 mg/kg i.v. given on Days 1 and 22 of Cycle 1 (priming phase)&#xD;
Nivolumab 480 mg i.v. given on Day 1 of Cycle 3 and then on Day 1 of each subsequent cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort E: NeoVax+Ipilimumab+Nivolumab (day 1&amp;15 each cycle)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NeoVax given on Days 1, 8, 15, and 22 of Cycle 1 (priming phase), and then on Day 1 of each subsequent cycle (boosting phase)&#xD;
Ipilimumab 1 mg/kg i.v. given every 6 weeks beginning on Day 1 of Cycle 1 (C1D1, C2D15, C4D1, C5D15, C7D1, C8D15 â€¦)&#xD;
Nivolumab 3 mg/kg i.v. given on Days 1 and 15 of each cycle (q2w) beginning on Day 1 of Cycle 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NeoVax</intervention_name>
    <description>At each vaccination time point, patients will receive up to 20 synthetic long peptides co-administered with 1.5 mg of poly-ICLC divided into a maximum of four injections (pools). Each pool (of vaccine + poly IC:LC) will be administered to one of the four limbs (right axilla, left axilla, right inguina, left inguina) by subcutaneous injection.</description>
    <arm_group_label>Cohort A: NeoVax+Nivolumab (start at time of progression)</arm_group_label>
    <arm_group_label>Cohort B: NeoVax+Nivolumab (start with Cycle 2)</arm_group_label>
    <arm_group_label>Cohort C: NeoVax + Nivolumab (start with Cycle 1)</arm_group_label>
    <arm_group_label>Cohort D: NeoVax+Ipilimumab+Nivolumab (start with Cycle 3)</arm_group_label>
    <arm_group_label>Cohort E: NeoVax+Ipilimumab+Nivolumab (day 1&amp;15 each cycle)</arm_group_label>
    <other_name>Synthetic long peptides plus poly-ICLC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody</description>
    <arm_group_label>Cohort A: NeoVax+Nivolumab (start at time of progression)</arm_group_label>
    <arm_group_label>Cohort B: NeoVax+Nivolumab (start with Cycle 2)</arm_group_label>
    <arm_group_label>Cohort C: NeoVax + Nivolumab (start with Cycle 1)</arm_group_label>
    <arm_group_label>Cohort D: NeoVax+Ipilimumab+Nivolumab (start with Cycle 3)</arm_group_label>
    <arm_group_label>Cohort E: NeoVax+Ipilimumab+Nivolumab (day 1&amp;15 each cycle)</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Ipilimumab is a recombinant, human monoclonal antibody that binds to the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4)</description>
    <arm_group_label>Cohort D: NeoVax+Ipilimumab+Nivolumab (start with Cycle 3)</arm_group_label>
    <arm_group_label>Cohort E: NeoVax+Ipilimumab+Nivolumab (day 1&amp;15 each cycle)</arm_group_label>
    <other_name>Yervoy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Research blood draw</intervention_name>
    <description>-Baseline, cycle 2 day 1, cycle 4 day 1, and time of progression or discontinuation of treatment</description>
    <arm_group_label>Cohort A: NeoVax+Nivolumab (start at time of progression)</arm_group_label>
    <arm_group_label>Cohort B: NeoVax+Nivolumab (start with Cycle 2)</arm_group_label>
    <arm_group_label>Cohort C: NeoVax + Nivolumab (start with Cycle 1)</arm_group_label>
    <arm_group_label>Cohort D: NeoVax+Ipilimumab+Nivolumab (start with Cycle 3)</arm_group_label>
    <arm_group_label>Cohort E: NeoVax+Ipilimumab+Nivolumab (day 1&amp;15 each cycle)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Leukapheresis for research</intervention_name>
    <description>-Baseline, cycle 4 day 1, and time of progression or discontinuation of treatment</description>
    <arm_group_label>Cohort A: NeoVax+Nivolumab (start at time of progression)</arm_group_label>
    <arm_group_label>Cohort B: NeoVax+Nivolumab (start with Cycle 2)</arm_group_label>
    <arm_group_label>Cohort C: NeoVax + Nivolumab (start with Cycle 1)</arm_group_label>
    <arm_group_label>Cohort D: NeoVax+Ipilimumab+Nivolumab (start with Cycle 3)</arm_group_label>
    <arm_group_label>Cohort E: NeoVax+Ipilimumab+Nivolumab (day 1&amp;15 each cycle)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly diagnosed histologically confirmed unmethylated glioblastoma multiforme (WHO&#xD;
             grade IV). Patients with secondary glioblastoma, in particular those who are IDH1 or&#xD;
             IDH2 mutant, will not be excluded. Unmethylated MGMT must be confirmed by a PCR-based&#xD;
             assay.&#xD;
&#xD;
          -  Patients who had craniotomy with biopsy, subtotal resection, total gross resection, or&#xD;
             re-resection will be permitted.&#xD;
&#xD;
          -  Consented to genome sequencing and dbGaP-based data sharing and has provided or will&#xD;
             provide germline (PBMC) and tumor DNA/RNA samples of adequate quality for sequencing.&#xD;
             (Acquisition of specimens for sequencing and the sequencing itself may be done as part&#xD;
             of routine care or another research project.)&#xD;
&#xD;
          -  At least 18 years of age.&#xD;
&#xD;
          -  Karnofsky performance status â‰¥ 60%&#xD;
&#xD;
          -  Normal bone marrow and organ function as defined below:&#xD;
&#xD;
               -  Absolute neutrophil count â‰¥ 1,500/mcL&#xD;
&#xD;
               -  Platelets â‰¥ 100,000/mcL&#xD;
&#xD;
               -  Total bilirubin â‰¤ 1.5 x institutional upper limit of normal (IULN)&#xD;
&#xD;
               -  AST(SGOT)/ALT(SGPT) â‰¤ 3.0 x IULN&#xD;
&#xD;
               -  Creatinine â‰¤ IULN OR creatinine clearance â‰¥ 60 mL/min/1.73 m2 for patients with&#xD;
                  creatinine levels above institutional normal&#xD;
&#xD;
          -  Systemic corticosteroid therapy is permitted provided dosing is no greater than 4 mg&#xD;
             per day (dexamethasone or equivalent) on the day of vaccine administration.&#xD;
&#xD;
          -  Bevacizumab will be allowed if given for symptomatic control of vasogenic edema and to&#xD;
             avoid high dose of corticosteroids.&#xD;
&#xD;
          -  Women of childbearing potential and men must agree to use adequate contraception&#xD;
             (hormonal or barrier method of birth control, abstinence) prior to study entry and for&#xD;
             the duration of study participation, including at least 5 months (for women of&#xD;
             childbearing potential) and at least 7 months (for men) after last dose of study drug.&#xD;
             Should a woman become pregnant or suspect she is pregnant while participating in this&#xD;
             study, she must inform her treating physician immediately.&#xD;
&#xD;
          -  Ability to understand and willingness to sign an IRB approved written informed consent&#xD;
             document (or that of legally authorized representative, if applicable).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  As this study aims to assess the immunogenicity of various vaccine plus adjuvant&#xD;
             combinations, no prior immunotherapy will be permitted.&#xD;
&#xD;
          -  Inadequate tissue acquisition to allow for neoantigen screening.&#xD;
&#xD;
          -  No candidate neoantigen identified during screening.&#xD;
&#xD;
          -  A history of other malignancy â‰¤ 3 years previous with the exception of non-melanoma&#xD;
             skin cancer, any in situ cancer that has been successfully resected and cured, treated&#xD;
             superficial bladder cancer, or any early-stage solid tumor that was successfully&#xD;
             resected without need for adjuvant radiation or chemotherapy.&#xD;
&#xD;
          -  Receiving any other investigational agents within 4 weeks of beginning study&#xD;
             treatment.&#xD;
&#xD;
          -  Known allergy, or history of serious adverse reaction to, vaccines such as&#xD;
             anaphylaxis, hives, or respiratory difficulty.&#xD;
&#xD;
          -  A history of allergic reactions attributed to compounds of similar chemical or&#xD;
             biologic composition to poly-ICLC or other agents used in the study.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements.&#xD;
&#xD;
          -  History of pre-existing immunodeficiency disorder or autoimmune condition requiring&#xD;
             immunosuppressive therapy. This includes inflammatory bowel disease, ulcerative&#xD;
             colitis, Crohn's disease, systemic vasculitis, scleroderma, psoriasis, multiple&#xD;
             sclerosis, hemolytic anemia, immune-mediated thrombocytopenia, rheumatoid arthritis,&#xD;
             systemic lupus erythematosus, SjÃ¶gren's syndrome, sarcoidosis, or other rheumatologic&#xD;
             disease or any other medical condition or use of medication which might make it&#xD;
             difficult for the patient to complete the full course of treatments or to generate an&#xD;
             immune response to vaccines.&#xD;
&#xD;
          -  Presence of clinically significant increased intracranial pressure (e.g. impending&#xD;
             herniation) or hemorrhage, uncontrolled seizures, or requirement for immediate&#xD;
             palliative treatment.&#xD;
&#xD;
          -  Pregnant and/or breastfeeding. Women of childbearing potential must have a negative&#xD;
             pregnancy test within 7 days of first dose of vaccine.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tanner Johanns, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 29, 2018</study_first_submitted>
  <study_first_submitted_qc>January 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2018</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
    <mesh_term>Poly ICLC</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 18, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/94/NCT03422094/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

